Inhibrx Biosciences, Inc. Total Assets
Inhibrx Biosciences, Inc. total assets. Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) holds total assets worth $183.97 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Inhibrx Biosciences, Inc. for the company's overall valuation and market capitalisation.
Total Assets of Inhibrx Biosciences, Inc. (2016–2025)
Total assets of Inhibrx Biosciences, Inc. from 2016 to 2025. This chart illustrates how Inhibrx Biosciences, Inc.'s total assets have evolved over time, based on quarterly financial data. See INBX share price today for real-time trading data and today's change.
Inhibrx Biosciences, Inc. - Asset Composition Analysis
Inhibrx Biosciences, Inc. Total Assets Breakdown (December 2025)
Inhibrx Biosciences, Inc. total assets breakdown as of December 2025. Inhibrx Biosciences, Inc.'s total assets of $183.97 Million consist of 90.7% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.8% |
| Accounts Receivable | $177.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Inhibrx Biosciences, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Inhibrx Biosciences, Inc. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inhibrx Biosciences, Inc.'s current assets represent 90.7% of total assets in 2025, a decrease from 95.9% in 2016.
- Cash Position: Cash and equivalents constituted 84.8% of total assets in 2025, down from 94.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Inhibrx Biosciences, Inc. Competitors by Total Assets
Key competitors of Inhibrx Biosciences, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
Inhibrx Biosciences, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.46 | 5.12 | 6.06 |
| Quick Ratio | 6.46 | 5.12 | 5.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $144.83 Million | $179.75 Million | $109.61 Million |
Inhibrx Biosciences, Inc. - Advanced Valuation Insights
This section examines the relationship between Inhibrx Biosciences, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 212.28 |
| Latest Market Cap to Assets Ratio | 7.23 |
| Asset Growth Rate (YoY) | -19.0% |
| Total Assets | $146.48 Million |
| Market Capitalization | $1.06 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Inhibrx Biosciences, Inc.'s assets at a significant premium (7.23x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Inhibrx Biosciences, Inc.'s assets decreased by 19.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual total assets of Inhibrx Biosciences, Inc. from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $146.48 Million | -18.97% |
| 2024-12-31 | $180.77 Million | -41.29% |
| 2023-12-31 | $307.89 Million | +5.85% |
| 2022-12-31 | $290.88 Million | +93.34% |
| 2021-12-31 | $150.45 Million | +4.67% |
| 2020-12-31 | $143.74 Million | +442.64% |
| 2019-12-31 | $26.49 Million | +165.31% |
| 2018-12-31 | $9.98 Million | -42.11% |
| 2017-12-31 | $17.25 Million | -18.93% |
| 2016-12-31 | $21.27 Million | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more